San Diego’s biotech sector, once a magnet for talent and capital, is now struggling with layoffs, vacant lab space, and dwindling opportunities for researchers.
At a Glance
- San Diego ranks third among U.S. biotech hubs but is experiencing rising unemployment and reduced funding.
- Vacant laboratory space in the region has sharply increased, reversing years of high demand.
- Former employees, including ex-Illumina staff, report more than a year without successful job placements.
- Venture capital funding is showing tentative signs of returning, though at lower levels than during the pandemic boom.
- A few biotech firms and stocks remain stable, hinting at possible long-term recovery.
From Boom to Freeze
For years, San Diego stood as one of the most dynamic life-science clusters in the country, trailing only Boston and the Bay Area. The region benefited from an influx of venture capital, a surge in lab construction, and steady hiring across startups and established companies. That expansion has ground to a halt.
Watch now: UC San Diego Health Layoffs: Impact on Clinical Staff · YouTube
The slowdown has been marked by a wave of layoffs, many hitting scientists and engineers from leading firms like Illumina. Instead of being quickly absorbed by neighboring companies, many of these workers remain unemployed months later. Analysts say this prolonged job drought reflects not just local conditions but broader shifts in biotech funding nationwide.
Empty Labs, Rising Pressure
Another visible sign of contraction is the glut of laboratory space. During the industry’s rapid growth phase, developers raced to add new facilities, confident demand would outstrip supply. Today, large portions of those labs sit vacant, a development almost unheard of just three years ago. Landlords and operators now face mounting financial strain as leases go unfilled, while entrepreneurs lack the capital to take advantage of discounted space.
The oversupply has ripple effects on the region’s ecosystem. Venture capital firms often see thriving lab occupancy as a sign of market health; today’s vacancies instead reinforce perceptions of an industry in retreat. The imbalance between available infrastructure and shrinking demand underscores the severity of the downturn.
Human Impact
Behind the statistics are displaced professionals navigating one of the most difficult hiring landscapes in decades. Vince Kato, a former Illumina engineer laid off in early 2024, has applied to dozens of roles without success. His experience highlights how deep the freeze runs: even highly trained scientists with years of experience struggle to find positions.
The challenges are compounded by San Diego’s high cost of living. Monthly rents that rank among the highest in the nation place intense financial pressure on job seekers, some of whom are leaving the region altogether. Others attempt to pivot into adjacent industries like medical devices or data science, though opportunities there are limited.
Signs of Resilience
Despite the headwinds, not all indicators point downward. Some local biotech firms continue to hold steady, supported by targeted investor confidence and niche scientific advances. A modest uptick in venture capital activity in recent months suggests cautious optimism that the sector’s downturn may not be permanent.
Stock performance also reveals small pockets of resilience, with a handful of companies outperforming broader market expectations. These gains are insufficient to reverse the general decline but hint at the potential for a long-term rebound if capital continues to re-enter the region. For now, however, San Diego’s biotech community faces a difficult recalibration from boomtown expansion to survival mode.
Sources
